Q1 2025 Earnings Report May 8, 2025 | Nasdaq: COLL Healthier people. Stronger communities. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events ...

Financial Data and Key Metrics Changes - The company reported a 23% year-over-year revenue growth, with net product revenues reaching $177.8 million [27] - GAAP net income was $2.4 million, a decrease from $27.7 million in the first quarter of 2024, impacted by acquisition-related expenses [29] - Non-GAAP adjusted EBITDA was $95.2 million, up 3% year over year [29] - The cash position increased to $197.8 million, up $35 million from year-end [30] Business Line Data and Key Metrics Changes - The ADHD medicine Jornay generated $28.5 million in net revenue, with a 24% year-over-year growth in prescriptions [7][27] - The pain portfolio generated $149.2 million in sales, reflecting a 3% year-over-year growth, with all three pain medicines showing single-digit growth [9][22] - BELBUCA net revenue was $51.7 million, up 2% year over year; Xtampza net revenue was $47.6 million, up 4%; and Nucynta franchise net revenue was $47.1 million, also up 4% [28] Market Data and Key Metrics Changes - Jornay's market share in the long-acting branded methylphenidate market increased to 20.3%, up 6.4% year over year [19] - The overall ADHD market is growing at about 5% to 6% annually [48] Company Strategy and Development Direction - The company is focused on three strategic priorities: driving growth in Jornay, maximizing the pain portfolio's value, and strategically deploying capital to enhance shareholder value [4][11] - The company aims to diversify its portfolio through disciplined business development and has authorized a $25 million accelerated share repurchase program [11][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the durability of the pain portfolio and its ability to generate significant cash flows [12][25] - The company is well-positioned to achieve its 2025 financial guidance and is focused on creating shareholder value [33] Other Important Information - The company completed the expansion of its ADHD sales force, adding approximately 55 new representatives, bringing the total to about 180 [9][20] - The company is undergoing leadership changes, with the founder retiring and new executives joining the team [10] Q&A Session Summary Question: How will Journey scripts trend as the school year ends? - Management noted that there is typically a slowdown in scripts towards the end of the school year, followed by an acceleration in the back-to-school season [36][38] Question: Is there potential to utilize JOURNEY PM technology for other compounds? - Management confirmed that discussions regarding the use of the technology for other compounds had occurred prior to the acquisition [40] Question: What is the appetite for business development deals? - Management indicated a disciplined approach to capital deployment, focusing on the right opportunities for business development while also prioritizing debt repayment and share repurchases [42][44] Question: What is the overall ADHD market growth? - The ADHD market is growing at about 5% to 6% annually [48] Question: What is the breakdown of the prescriber base for Jornay? - The prescriber base consists of approximately 40% pediatricians, 40% neuropsychiatrists, and the remaining 20% split between PCPs and mid-level providers [48] Question: What is the size of the sales organization contemplated for Jornay? - Management stated that the current sales force of 180 is appropriate for the target audience, with regular evaluations for potential adjustments [56]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37372 Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) Virginia (State o ...

Exhibit 99.1 Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress – Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Rec ...

Financial Performance - Collegium Pharmaceutical reported Q1 2025 net revenue of $177.8 million, representing a 23% increase year-over-year from $144.9 million in Q1 2024 [9][24] - The company generated $149.2 million from its pain portfolio, up 3% year-over-year, with all three core products showing revenue growth [10][24] - Net revenue from Jornay PM reached $28.5 million in Q1 2025, with a year-over-year prescription growth of 24% [6][9] Strategic Initiatives - The company completed an expansion of its Jornay PM field force, adding 55 new sales representatives, bringing the total to approximately 180 [3][6] - Collegium reaffirmed its full-year 2025 guidance, projecting product revenues between $735 million and $750 million [8] - The board authorized a $25 million accelerated share repurchase program to enhance shareholder value [3][10] Cash Position and Debt Management - As of the end of Q1 2025, Collegium had cash, cash equivalents, and marketable securities totaling $197.8 million, an increase from $162.8 million at the end of 2024 [3][26] - The company paid down an additional $16.1 million in debt during the quarter [3][10] Leadership and Corporate Updates - Collegium made significant additions to its leadership team and board of directors, including the appointment of new executive leaders and board members [10][10] - The company was recognized as a Top Workplace by USA TODAY and a Best Places to Work honoree by the Boston Business Journal [10][10]

Wall Street expects a year-over-year decline in earnings on higher revenues when Collegium Pharmaceutical (COLL) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 8, 2025, might help the stock move higher if these key numbers are better t ...

STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the "Collegium Pharmaceutical Q1 2 ...

Group 1 - Collegium Pharmaceutical, Inc. will participate in a fireside chat at the 24th Annual Needham Healthcare Conference from April 7-10, 2025 [1] - The fireside chat is scheduled for April 8, 2025, at 9:30 a.m. ET and will be available via live webcast [1] - A replay of the webcast will be accessible on the company's website for 90 days post-presentation [1] Group 2 - Collegium is focused on becoming a leading, diversified biopharmaceutical company aimed at improving the lives of individuals with serious medical conditions [2] - The company has a strong portfolio in responsible pain management medications and has recently acquired Jornay PM®, a treatment for ADHD, marking its entry into neuropsychiatry [2] - Collegium's growth strategy includes expanding its commercial portfolio with Jornay PM as the primary growth driver and managing capital deployment in a disciplined manner [2]

STOUGHTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present four posters highlighting real-world patient data from its differentiated pain portfolio at PainConnect 2025, the American Academy of Pain Medicine (AAPM)’s Annual Meeting, being held in Austin, TX, from April 3-6, 2025. Among these, the poster titled “Route of Administration and Other Clinical Outcomes Among Exposures to Buprenorphine Pain Medications and Schedule II Opioids” h ...

Core Points - Collegium Pharmaceutical, Inc. announced significant changes to its Board of Directors and executive leadership team as part of a new growth phase [1][2][3] Board of Directors Changes - Michael Heffernan, Founder and Chairman, and Gwen A. Melincoff, Board Member, will retire at the Annual General Meeting (AGM) on May 15, 2025 [2] - Gino Santini, the Board's Lead Independent Director, will be appointed as the new Chairman [2] - Dr. Carlos Paya has been nominated to the Board for shareholder approval at the AGM [2] Executive Leadership Appointments - David Dieter has been appointed as Executive Vice President, General Counsel [1][4] - Jane Gonnerman has been appointed as Executive Vice President, Strategy and Corporate Development [1][4] - Dean J. Patras has been appointed as Chief People Officer [1][4] Leadership Experience - Dr. Carlos Paya brings over 30 years of experience in the biopharmaceutical industry, previously serving as CEO of Immune Design Corp. and holding senior roles at Elan Pharmaceuticals and Eli Lilly [4][5] - David Dieter previously served as Vice President, Legal at Horizon Therapeutics, managing corporate and commercial legal matters [6] - Jane Gonnerman was Senior Vice President at Amgen, responsible for the rare disease portfolio and played a key role in the $28 billion sale of Horizon to Amgen [7] - Dean J. Patras held leadership roles at Amgen and Horizon, focusing on human resources integration following acquisitions [8] Company Strategy - Collegium aims to enhance its growth by focusing on its pain management portfolio and the recently acquired Jornay PM, a treatment for ADHD [4][9] - The company is committed to improving the lives of individuals with serious medical conditions through its diversified biopharmaceutical offerings [9]